Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
5.4
3.9
Journals
JCM
Special Issues
Review Special Issue Series: Recent Advances in Pharmacology
share announcement

Review Special Issue Series: Recent Advances in Pharmacology

A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Pharmacology".

Deadline for manuscript submissions: 20 June 2024 | Viewed by 406

Special Issue Editors

Dr. Alfredo Vannacci

E-Mail Website
Guest Editor
Department of Neurosciences, Psychology, Drug Research and Child Health, Section of Pharmacology and Toxicology, University of Florence, 50141 Florence, Italy
Interests: pharmacovigilance; pharmacology; toxicology; pharmacoepidemiology; drug safety; clinical pharmacy; medical pharmacology
Special Issues, Collections and Topics in MDPI journals
Dr. Giada Crescioli

E-Mail Website
Guest Editor
1. Department of Neurosciences, Psychology, Drug Research and Child Health, Section of Pharmacology and Toxicology, University of Florence, 50141 Florence, Italy
2. Tuscan Regional Centre of Pharmacovigilance, 50122 Florence, Italy
Interests: clinical pharmacology and toxicology; pharmacovigilance and pharmacoepidemiology
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Clinical pharmacology is an independent emerging discipline that has formed in recent decades. The main research purposes are to clarify the efficacy of new drugs; the rules of their transport and transformation in the body; the nature and extent of toxic and side effects; drug interactions and their mechanisms of action, including pharmacokinetics, pharmacodynamics, pharmacogenomics; topics such as pharmacoepidemiology and pharmacovigilance; and the safety of medications used throughout a human lifespan, as evidenced by pregnant women and the elderly.

Based on the research results, a reasonable dosing regimen is formulated to guide the rational, safe and effective clinical use of drugs. Finally, an accurate and scientific evaluation of the drug is made to promote the development of new drugs and provide a scientific basis for drug management.

We have launched this Special Issue "Review Special Issue Series: Recent Advances in Pharmacology" and we encourage you and your colleagues to submit your latest articles related to clinical pharmacology to provide scholars in this field with the latest insights and clinical studies that will broaden the scope of pharmacology knowledge.

Dr. Alfredo Vannacci
Dr. Giada Crescioli
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • clinical pharmacology
  • pharmacovigilance
  • pharmacokinetics
  • pharmacodynamics
  • pharmacogenetics
  • pharmacoepidemiology
  • pharmacometrics
  • pregnancy and pediatrics
  • adults and elderly
  • safety
  • toxic and side effects
  • drug reactions

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

13 pages, 2651 KiB  
Article
Drug Use Patterns in Myasthenia Gravis: A Real-World Population-Based Cohort Study in Italy
by Marco Finocchietti, Giada Crescioli, Olga Paoletti, Paola Brunori, Francesco Sciancalepore, Marco Tuccori, Antonio Addis, Alfredo Vannacci, Niccolò Lombardi, Ursula Kirchmayer and The CAESAR Study Group
J. Clin. Med. 2024, 13(11), 3312; https://doi.org/10.3390/jcm13113312 - 4 Jun 2024
Viewed by 181
Abstract
Background: In the context of a comparative study of efficacy and safety of drugs used in rare neuromuscular and neurodegenerative diseases (CAESAR—call AIFA_FV_2012-13-14), we assessed the use patterns of drugs indicated for myasthenia gravis (MG). Methods: A retrospective cohort study was [...] Read more.
Background: In the context of a comparative study of efficacy and safety of drugs used in rare neuromuscular and neurodegenerative diseases (CAESAR—call AIFA_FV_2012-13-14), we assessed the use patterns of drugs indicated for myasthenia gravis (MG). Methods: A retrospective cohort study was conducted based on administrative healthcare data. For a cohort of MG patients, prevalent and incident use of pyridostigmine (Py) and other indicated drugs in the first year after case identification was evaluated. Prevalent combined use of major therapies (azathioprine (Az), prednisone (Pr), vitamin D (Vd)) stratified by Py use was assessed, and a comparison between therapies at the time of MG identification and during the first year of follow-up was performed. Results: We included 2369 MG patients between 2013 and 2019. Among them, prevalent and incident Py users were 38.4% and 22.0%, respectively. In the first year of follow-up, the use of Pr was observed in 74.5% of Py prevalent users and in 82.0% of Py incident users, respectively; the use of Az was observed in 24.9% and 23.0%, respectively; and the use of Vd was observed in 53.3% and 48.2%, respectively. Among 910 Py prevalent users, 13.1% also used Az, Pr, and Vd, while 15.3% used none of these. Among 938 non-Py users, 2.7% used Az, Pr, and Vd, while 53.8% used none of these. During the first year, an increase in combined therapies was evident in incident Py users. Conclusions: Our results suggest that, for some MG patients, there may be a need for treatments that combine a rapid onset of benefit with long-term and consistent disease control. These issues may be addressed by the new treatments currently being developed. To date, more studies are needed to address the heterogeneity, quality, and generalizability of the existing data and to evaluate patterns of use, efficacy, and safety of new or emerging therapies for MG. Full article
(This article belongs to the Special Issue Review Special Issue Series: Recent Advances in Pharmacology)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop